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SUMMARY
Objective: We describe a woman with essential thrombocythemia (ET) who experienced a successful pregnancy
with no specific treatment.
Case Report: A 30-year-old primiparous female was incidentally found to have ET with no specific symptoms
at a gestational age (GA) of 8 weeks. Initially, her platelet count was 1,100 = 109/L, which declined to a median
of 678 = 109/L (range, 663–753 = 109/L) during the second and third trimesters, without treatment. A healthy
male baby weighing 3,330 g was born by cesarean delivery due to breech presentation at a GA of 38 weeks.
The pre-delivery platelet count was 605 = 109/L. No bleeding or major thromboembolic complications were
encountered in the peripartum period. The maternal platelet count returned to 1,230 = 109/L and 1,320 =
109/L, respectively, at 2 months and 3 years after delivery. The child had normal physical and mental development
at 2 years and 9 months old.
Conclusion: Management of ET during pregnancy is still controversial. Platelet count, either at diagnosis or
at conception, fails to predict the pregnancy outcome. The treatment plan should be based on clinical judgment
that weighs the risk of thrombohemorrhagic complications against related morbidity and side effects. [Taiwanese
J Obstet Gynecol 2004;43(4):237–239]
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Introduction
Essential thrombocythemia (ET) is a rare myeloprolif-
erative disease manifesting an elevated platelet count
and megakaryocytic hyperplasia. The diagnosis is made
after the exclusion of secondary thrombocytosis (Phila-
delphia chromosome negative, normal red blood cell
mass, normal iron status, absence of chronic infec-
tion and no systemic disease or malignancy), following
the criteria of the Polycythemia Vera Study Group [1].
The median age at diagnosis is approximately 60 years,
and as many as 20% of patients are diagnosed before
the age of 40 years. It is more common in women than
in men (female:male, 1.6:1). The clinical manifestations
of ET include vasomotor disturbances (headaches, diz-
ziness, acral dysesthesia, visual symptoms or livedo
reticularis), thrombohemorrhage, frequent miscarriages
during the first trimester and, rarely, transformations
into acute myeloid leukemia or myelofibrosis with
myeloid metaplasia, although one-third of patients are
asymptomatic. There is no current consensus on the
optimal management of ET during pregnancy. Manage-
ment varies from no treatment, through anti-platelet
aggregants (aspirin and/or heparin) to the use of platelet
apheresis or cytoreductive therapy (interferon-alpha
[IFN-_], hydroxyurea, busulfan or anagrelide). Obstetric
outcomes are variable, ranging from early miscarriage
to normal term delivery.
We report the case of a pregnant woman with ET and
the associated clinical course and pregnancy outcome.
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Case Report
A 30-year-old primiparous woman at a gestational age
(GA) of 8 weeks was referred from a local clinic because
of thrombocytosis (platelet count, 1,100 = 109/L) on
routine complete blood analysis. She was asymptomatic,
and a survey of possible etiologies of thrombocytosis
was performed. The Cr-51 red cell volume study showed
normal red cell mass. The leukocyte alkaline phosphatase
score was within the normal range. Bone marrow biopsy
over the posterior iliac crest favored ET. Upper abdomi-
nal sonography revealed neither hepatomegaly nor
splenomegaly. Thus, a diagnosis of ET was established
according to the criteria defined by the Polycythemia
Vera Study Group [1]. No specific treatment was given
on the recommendation of the hematologist, and the
platelet count was routinely checked every 4 weeks. The
platelet count declined to a median of 678 = 109/L
(range, 663–753 = 109/L) during the second and third
trimesters. Serial ultrasound examination revealed nor-
mal fetal growth and normal umbilical arterial resis-
tance. The pregnancy course was uneventful. A healthy
male baby weighing 3,330 g was born by cesarean
delivery due to breech presentation at a GA of 38
weeks. The maternal platelet count immediately before
delivery was 605 = 109/L. No bleeding or major throm-
boembolic complications were encountered in the
peripartum period. The platelet count was 1,230 = 109/L
and 1,320 = 109/L at 2 months and 3 years, respec-
tively, after delivery, despite no treatment (Figure). The
child had normal physical and mental development at
2 years and 9 months old.
Discussion
Among pregnancies with ET, 50.3% result in normal
babies and 25.9% in spontaneous abortions (mostly in
the first trimester) [2]. A trend towards a decrease in the
platelet count is observed in most cases of ET during
pregnancy, even without treatment. Mechanisms for
this include increased blood volume, higher concen-
tration of estrogen and adrenocortical hormones, release
of IFN-like factor from the placenta or fetus that down-
regulates platelet production, and a cytokine-mediated
decrease in megakaryocyte number.
Therapy with aspirin may reduce the risk of spon-
taneous abortion in the first trimester and intrauterine
fetal death when compared with no treatment, although
thrombotic issues and bleeding during the postpartum
period do not significantly differ between patients with
and without aspirin treatment [2]. Although cyto-
reductive therapy during pregnancy may increase the
possibility of teratogenicity, IFN-_ seems to be safer
than hydroxyurea. Amniotic fluid always contains sig-
nificant amounts of IFN-_, and a physiologic role in
the growth and development of the normal placenta
and in the regulation of the maternofetal graft inter-
action has been postulated [3]. This suggests that
exogenous IFN might not be harmful to the fetus.
Platelet apheresis can be used in acute situations
such as massive thrombosis or hemorrhage with no risk
to the fetus, but there are disadvantages, including the
expense, the amount of time consumed and the rapid
return to pretreatment levels. In addition, no significant
correlation has been shown between the thrombotic
risk and platelet count.
The platelet count, either at diagnosis or at concep-
tion, clearly does not predict pregnancy outcome with
ET [4]. Thus, low-risk asymptomatic patients who have
no history of thrombosis are usually managed by ob-
servation alone, regardless of the degree of thrombo-
cytosis. In contrast, high-risk patients aged more than
60 years or who have a history of thrombosis may
benefit from cytoreductive therapy [5]. We conclude
that the optimal management of ET in pregnancy is
still debatable. The treatment plan should be based
on clinical judgment that weighs the risk of thrombo-
hemorrhagic complications against the related morbid-
ity and side effects.
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Figure. Platelet count during pregnancy and postpartum (PP).
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